Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma

Clinical Cancer Research

Volumn 15, Issue 18, 2009, Pages 5878-5887

  Schetter, Aaron J ^a   Giang, Huong Nguyen ^a,b   Bowman, Elise D ^a   Mathé, Ewy A ^a   Siu, Tsan Yuen ^c   Hawkes, Jason E ^a,b   Croce, Carlo M ^d   Suet, Yi Leung ^c   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORDANE; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12P35; INTERLEUKIN 17; INTERLEUKIN 23P19; INTERLEUKIN 6; INTERLEUKIN 8; MICRORNA; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CANCER MORTALITY; CANCER STAGING; COLON ADENOCARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TUMOR GENE; VALIDATION STUDY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COLONIC NEOPLASMS; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATION; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 70349454207     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0627     Document Type: Article

References (50)

1. Aaltonen LA, Hamilton SR, World Health Organization, International Agency for Research on Cancer. Pathology and genetics of tumours of the digestive system. Lyon Oxford: IARC Press; Oxford University Press (distributor); 2000.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
3. Chua YJ, Zalcberg JR. Progress and challenges in the adjuvant treatment of stage II and III colon cancers. Expert Rev Anticancer Ther 2008;8:595-604. (Pubitemid 351818354)
4. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 2008;134:1296-1310
5. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007;121:2373-2380 (Pubitemid 350022405)
6. DeNardo DG, Johansson M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev 2008;27:11-18
7. Ekbom A, Helmick C, Zack M, Adami HO. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 1990;336:357-359 (Pubitemid 20264156)
8. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228-1233 (Pubitemid 20366527)
9. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91:854-862 (Pubitemid 32173312)
10. Cha YI, DuBois RN. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 2007;58:239-252 (Pubitemid 46706512)
11. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117:1175-1183 (Pubitemid 46718402)
12. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008;371:771-783
13. Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet 1987;1:1303-1306 (Pubitemid 17072200)
14. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-1964 (Pubitemid 44498003)
15. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-2666 (Pubitemid 41817714)
16. Landi S, Bottari F, Gemignani F, et al. Interleukin-4 and interleukin-4 receptor polymorphisms and colorectal cancer risk. Eur J Cancer 2007;43:762-768 (Pubitemid 46509446)
17. Lurje G, Zhang W, Schultheis AM, et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol 2008.
18. Wilkening S, Tavelin B, Canzian F, et al. Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis 2008;29:1202-1206 (Pubitemid 351964881)
19. Pages F, Berger A, Henglein B, et al. Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int J Cancer 1999;84:326-330 (Pubitemid 29256763)
20. Berghella AM, Contasta I, Pellegrini P, Del Beato T, Adorno D. Are immunological mechanisms involved in colon cancer and are they possible markers for biotherapy improvement? Cancer Biother Radiopharm 2006;21:468-487
21. Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99-111. (Pubitemid 44202603)
22. Seike M, Yanaihara N, Bowman ED, et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst 2007;99:1257-1269 (Pubitemid 47299904)
23. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-1801 (Pubitemid 41549891)
24. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-647 (Pubitemid 40343076)
25. Volinia S, Calin GA, Liu CG, et al. A micro- RNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-2261 (Pubitemid 43271657)
26. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-198 (Pubitemid 43357945)
27. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-833 (Pubitemid 40839734)
28. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299:425-436
29. Moschos SA, Williams AE, Perry MM, Birrell MA, Belvisi MG, Lindsay MA. Expression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti-inflammatory action of glucocorticoids. BMC Genomics 2007;8:240.
30. Wu H, Neilson JR, Kumar P, et al. miRNA profiling of naive, effector and memory CD8 T cells. PLoS ONE 2007;2:e1020. (Pubitemid 351560146)
31. Loffler D, Brocke-Heidrich K, Pfeifer G, et al. Interleukin- 6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007;110:1330-1333 (Pubitemid 47281433)
32. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004;350:1828-1837
33. Holm S. A simple sequentially rejective multiple test procedure. Scand Journal of Statist 1979;6:65-70.
34. Hata K, Andoh A, Shimada M, et al. IL-17 stimulates inflammatory responses via NF-κB and MAP kinase pathways in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol 2002;282:G1035-44. (Pubitemid 34651610)
35. Lo CH, Lee SC, Wu PY, et al. Antitumor and antimetastatic activity of IL-23. J Immunol 2003;171:600-607
36. Hofseth LJ, Saito S, Hussain SP, et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A 2003;100:143-148 (Pubitemid 36078042)
37. Le Gouvello S, Bastuji-Garin S, Aloulou N, et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008;57:772-779 (Pubitemid 351716970)
38. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
39. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res 2008;36:D149-53.
40. Fujita S, Ito T, Mizutani T, et al. miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J Mol Biol 2008;378:492-504.
41. Seike M, Goto A, Okano T, et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer from never-smokers. Proc Natl Acad Sci U S A 2009;106:12085-12090
42. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008;14:6735-6741
43. McDermott DF. The application of high-dose interleukin-2 for metastatic renal cell carcinoma. Med Oncol 2009;26 Suppl 1:13-17
44. O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 2008;223:114-131 (Pubitemid 351986180)
45. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-725
46. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-146 (Pubitemid 37328691)
47. Tartour E, Fossiez F, Joyeux I, et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 1999;59:3698-3704 (Pubitemid 29381875)
48. Numasaki M, Watanabe M, Suzuki T, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005;175:6177-6189 (Pubitemid 41508106)
49. Numasaki M, Fukushi J, Ono M, et al. Interleukin- 17 promotes angiogenesis and tumor growth. Blood 2003;101:2620-2627 (Pubitemid 36857622)
50. Weiner LM. Cancer immunotherapy-the end-game begins. N Engl J Med 2008;358:2664-2665